Suchergebnisse - "Adedokun, Omoniyi J"

PubPharm (56)

1

Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024

von Colombel, J. | Sands, B. | Gasink, C. | +10

ErratumIn: Clin Gastroenterol Hepatol. 2024 Apr 3;:. - PMID 38582496

2

Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease

enthalten in: Clinical therapeutics | 2022

von Adedokun, O. | Xu, Z. | Gasink, C. | +3

3

Guselkumab for the Treatment of Crohn's Disease : Induction Results From the Phase 2 GALAXI-1 Study

enthalten in: Gastroenterology | 2022

von Sandborn, W. | D'Haens, G. | Reinisch, W. | +18

ErratumIn: Gastroenterology. 2023 Dec;165(6):1588. - PMID 37737816

4

Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease : The IM-UNITI Trial

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Sandborn, W. | Rebuck, R. | Wang, Y. | +11

5

Population Pharmacokinetic and Exposure-Response Model Simulations : Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis

enthalten in: Clinical therapeutics | 2022

von Lee, J. | Broadwell, A. | Fan, Y. | +6

6

Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease : Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study

enthalten in: Journal of Crohn's & colitis | 2021

von Rosh, J. | Turner, D. | Griffiths, A. | +7

7

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Panaccione, R. | Danese, S. | Sandborn, W. | +14

ErratumIn: Aliment Pharmacol Ther. 2021 May;53(9):1057-1060. - PMID 33831243

8

Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC : PURSUIT PEDS PK Long-Term Study Results

enthalten in: Crohn's & colitis 360 | 2020

von Hyams, J. | O'Brien, C. | Padgett, L. | +10

9

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2020

von Adedokun, O. | Xu, Z. | Marano, C. | +11

10

Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis

enthalten in: Journal of clinical pharmacology | 2020

von Xu, Y. | Hu, C. | Chen, Y. | +5

1
2
3
4
5
6
Nächster »
[6]